View Older Stories View More Recent Stories

Mar 21, 2023 02:00AM Press Release: Dupixent® (dupilumab) approved by European Commission as first and only targeted medicine for children as young as six months old with severe atopic dermatitis 
Mar 21, 2023 01:59AM Dupixent® (dupilumab) Approved by European Commission as First and Only Targeted Medicine for Children as Young as Six Months Old with Severe Atopic Dermatitis
Mar 21, 2023 01:59AM Dupixent® (dupilumab) Approved by European Commission as First and Only Targeted Medicine for Children as Young as Six Months Old with Severe Atopic Dermatitis
Mar 20, 2023 05:57AM Regeneron (REGN) and Sanofi (SNY) Report Dupixent Shows Significant Improvements in Signs and Symptoms of Moderate-to-severe Atopic Hand and Foot Dermatitis
Mar 18, 2023 10:00AM Press Release: Dupixent® (dupilumab) late-breaking data at AAD show significant improvements in signs and symptoms of moderate-to-severe atopic hand and foot dermatitis
Mar 18, 2023 10:00AM Dupixent® (dupilumab) Late-Breaking Data at AAD Show Significant Improvements in Signs and Symptoms of Moderate-to-severe Atopic Hand and Foot Dermatitis
Mar 18, 2023 10:00AM Dupixent® (dupilumab) Late-Breaking Data at AAD Show Significant Improvements in Signs and Symptoms of Moderate-to-severe Atopic Hand and Foot Dermatitis
Mar 14, 2023 10:56PM Students Win More Than $1.8 Million at 2023 Regeneron Science Talent Search for Remarkable Scientific Research on RNA Molecule Structure, Media Bias, and Diagnostics for Pediatric Heart Disease
Mar 14, 2023 09:30PM Students Win More Than $1.8 Million at 2023 Regeneron Science Talent Search for Remarkable Scientific Research on RNA Molecule Structure, Media Bias, and Diagnostics for Pediatric Heart Disease
Mar 14, 2023 09:30PM Students Win More Than $1.8 Million at 2023 Regeneron Science Talent Search for Remarkable Scientific Research on RNA Molecule Structure, Media Bias, and Diagnostics for Pediatric Heart Disease
Mar 7, 2023 01:00AM Dupixent® (dupilumab) Application for Treatment of Chronic Spontaneous Urticaria (CSU) in Adults and Adolescents Aged 12 Years and Older Accepted for FDA Review
Mar 7, 2023 01:00AM Press Release: Dupixent® (dupilumab) application for treatment of chronic spontaneous urticaria (CSU) in adults and adolescents accepted for FDA review
Mar 7, 2023 01:00AM Dupixent® (dupilumab) Application for Treatment of Chronic Spontaneous Urticaria (CSU) in Adults and Adolescents Aged 12 Years and Older Accepted for FDA Review
Mar 1, 2023 05:51AM Regeneron (REGN) Announces FDA Approval of Kevzara
Feb 28, 2023 08:00PM Kevzara® (sarilumab) Approved by FDA as First and Only Biologic Indicated for Patients with Polymyalgia Rheumatica
Feb 28, 2023 08:00PM Kevzara® (sarilumab) Approved by FDA as First and Only Biologic Indicated for Patients with Polymyalgia Rheumatica
Feb 24, 2023 07:45AM Regeneron (REGN) Reports Libtayo in Combination with Chemotherapy Receives Positive CHMP Opinion for the Treatment of Advanced PD-L1 NSCLC
Feb 24, 2023 07:45AM Libtayo® (cemiplimab) in Combination with Chemotherapy Receives Positive CHMP Opinion for the Treatment of Advanced PD-L1 Positive Non-small Cell Lung Cancer (NSCLC)
Feb 24, 2023 07:45AM Libtayo® (cemiplimab) in Combination with Chemotherapy Receives Positive CHMP Opinion for the Treatment of Advanced PD-L1 Positive Non-small Cell Lung Cancer (NSCLC)
Feb 23, 2023 07:06AM Regeneron (REGN) Announces Aflibercept 8 mg BLA Accepted for FDA Priority Review
Feb 23, 2023 07:00AM Aflibercept 8 mg BLA for Treatment of Wet Age-Related Macular Degeneration and Diabetic Macular Edema Accepted for FDA Priority Review
Feb 23, 2023 07:00AM Aflibercept 8 mg BLA for Treatment of Wet Age-Related Macular Degeneration and Diabetic Macular Edema Accepted for FDA Priority Review
Feb 21, 2023 07:03AM Regeneron (REGN) Announces Pozelimab BLA for Treatment of Children and Adults with Ultra-rare CHAPLE Disease Accepted for FDA Priority Review
Feb 21, 2023 07:01AM Regeneron (REGN) Announces Pozelimab BLA for Treatment of Children and Adults with Ultra-rare CHAPLE Disease Accepted for FDA Priority Review
Feb 21, 2023 07:00AM Pozelimab (C5 Antibody) BLA for Treatment of Children and Adults with Ultra-rare CHAPLE Disease Accepted for FDA Priority Review
Feb 21, 2023 07:00AM Pozelimab (C5 Antibody) BLA for Treatment of Children and Adults with Ultra-rare CHAPLE Disease Accepted for FDA Priority Review
Feb 8, 2023 06:45PM EYLEA® (aflibercept) Injection Approved as the First Pharmacologic Treatment for Preterm Infants with Retinopathy of Prematurity (ROP) by the FDA
Feb 8, 2023 06:45PM EYLEA® (aflibercept) Injection Approved as the First Pharmacologic Treatment for Preterm Infants with Retinopathy of Prematurity (ROP) by the FDA
Feb 3, 2023 06:30AM Regeneron Reports Fourth Quarter and Full Year 2022 Financial and Operating Results
Jan 31, 2023 04:01PM Regeneron Announces Investor Conference Presentations
Jan 31, 2023 04:01PM Regeneron Announces Investor Conference Presentations
Jan 30, 2023 05:51AM Regeneron (REGN) Announces Dupixent Approved in EU for Eosinophilic Esophagitis
Jan 30, 2023 01:00AM Press Release:  Dupixent® (dupilumab) approved by European Commission as the first and only targeted medicine indicated for eosinophilic esophagitis
Jan 30, 2023 01:00AM Dupixent® (dupilumab) Approved by European Commission as the First and Only Targeted Medicine Indicated for Eosinophilic Esophagitis
Jan 30, 2023 01:00AM Dupixent® (dupilumab) Approved by European Commission as the First and Only Targeted Medicine Indicated for Eosinophilic Esophagitis
Jan 27, 2023 05:50AM Regeneron (REGN) Announces Dupixent Recommended for Expanded EU Approval to Treat Children as Young as Six Months Old with Severe Atopic Dermatitis
Jan 27, 2023 01:00AM Press Release: Dupixent® (dupilumab) recommended for expanded EU approval by the CHMP to treat children as young as six months old with severe atopic dermatitis
Jan 27, 2023 12:59AM Dupixent® (dupilumab) Recommended for Expanded EU Approval by the CHMP to Treat Children as Young as Six Months Old with Severe Atopic Dermatitis
Jan 27, 2023 12:59AM Dupixent® (dupilumab) Recommended for Expanded EU Approval by the CHMP to Treat Children as Young as Six Months Old with Severe Atopic Dermatitis
Jan 24, 2023 12:02PM Top 40 High School Scientists Selected as Finalists in the Regeneron Science Talent Search, the Nation's Oldest and Most Prestigious Science and Math Competition
Jan 24, 2023 12:00PM Top 40 High School Scientists Selected as Finalists in the Regeneron Science Talent Search, the Nation’s Oldest and Most Prestigious Science and Math Competition
Jan 24, 2023 12:00PM Top 40 High School Scientists Selected as Finalists in the Regeneron Science Talent Search, the Nation’s Oldest and Most Prestigious Science and Math Competition
Jan 6, 2023 09:11AM 2seventy bio (TSVT) Announces Expanded Translational Collaboration with Regeneron (REGN) to Develop New Cell Therapy-Based Combinations for Solid Tumors
Jan 3, 2023 04:01PM Regeneron to Report Fourth Quarter and Full Year 2022 Financial and Operating Results and Host Conference Call and Webcast on February 3, 2023
Jan 3, 2023 04:01PM Regeneron to Report Fourth Quarter and Full Year 2022 Financial and Operating Results and Host Conference Call and Webcast on February 3, 2023
Dec 23, 2022 08:31AM Regeneron (REGN) Announces Libtayo Approved in Japan for Advanced or Recurrent Cervical Cancer
Dec 23, 2022 08:30AM Libtayo® (cemiplimab) Approved in Japan for Advanced or Recurrent Cervical Cancer
Dec 22, 2022 05:13AM Regeneron (REGN) Reports Publication of Positive Phase 3 Dupixent Data in Eosinophilic Esophagitis
Dec 21, 2022 05:29PM Positive Dupixent® (dupilumab) Phase 3 Results in Adults and Adolescents with Eosinophilic Esophagitis Published in the New England Journal of Medicine
Dec 19, 2022 04:01PM Regeneron Announces Presentation at the 41st Annual J.P. Morgan Healthcare Conference
View More Recent Stories View Older Stories